{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:45:47Z","timestamp":1791395147393,"version":"4.3.3"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide have been shown to induce substantial weight loss and improve cardiometabolic risk factors in patients living with obesity. However, most individuals regain weight after abrupt withdrawal of semaglutide, with reversal of its beneficial cardiometabolic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We propose a randomized controlled trial to determine whether a gradual dose reduction of semaglutide prior to complete discontinuation is associated with differential changes in weight and cardiometabolic profile as compared to immediate treatment cessation. Individuals living with obesity without preexisting cardiovascular disease who are receiving semaglutide for weight management and have achieved prior weight reduction of at least 10% with no further weight loss over past 12 weeks will be randomized to either gradual dose reduction over 16 weeks or abrupt treatment discontinuation. The primary outcome will be the difference in body weight change (%) between the study groups. Secondary outcomes will include 24-hour ambulatory blood pressure and fasting ghrelin levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>We hypothesize that gradual reduction of semaglutide will be associated with less weight regain and cardiometabolic deterioration compared with immediate cessation. This study addresses an important real-world problem regarding treatment discontinuation strategies and may inform future approaches for long-term obesity management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT07294950 (ClinicalTrials.gov).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0354237","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:23:20Z","timestamp":1785173000000},"page":"e0354237","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination \u2013 The REST trial study protocol"],"prefix":"10.1371","volume":"21","author":[{"given":"Taras","family":"Yevusiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna","family":"Weisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Retnakaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Wharton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Drucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1064-0100","authenticated-orcid":true,"given":"Caroline K.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"pone.0354237.ref001","unstructured":"Statistics Canada. Overweight and obesity in adults, 2018. https:\/\/www150.statcan.gc.ca\/n1\/pub\/82-625-x\/2019001\/article\/00005-eng.htm"},{"issue":"2","key":"pone.0354237.ref002","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jcjd.2013.02.059","article-title":"The public health burden of obesity in Canada","volume":"37","author":"I Janssen","year":"2013","journal-title":"Can J Diabetes"},{"key":"pone.0354237.ref003","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2458-9-88","article-title":"The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis","volume":"9","author":"DP Guh","year":"2009","journal-title":"BMC Public Health"},{"issue":"11","key":"pone.0354237.ref004","doi-asserted-by":"crossref","first-page":"758","DOI":"10.7326\/0003-4819-159-11-201312030-00008","article-title":"Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis","volume":"159","author":"CK Kramer","year":"2013","journal-title":"Ann Intern Med"},{"issue":"23","key":"pone.0354237.ref005","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1000367","article-title":"Body-mass index and mortality among 1.46 million white adults","volume":"363","author":"A Berrington de Gonzalez","year":"2010","journal-title":"N Engl J Med"},{"issue":"31","key":"pone.0354237.ref006","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"S Wharton","year":"2020","journal-title":"CMAJ"},{"issue":"1","key":"pone.0354237.ref007","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/oby.20662","article-title":"Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study","volume":"22","author":"Look AHEAD Research Group","year":"2014","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"pone.0354237.ref008","first-page":"211","article-title":"Weight loss is a useful therapeutic objective","volume":"31","author":"CK Kramer","year":"2015","journal-title":"Can J Cardiol"},{"issue":"11","key":"pone.0354237.ref009","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"JPH Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0354237.ref010","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy","volume":"325","author":"TA Wadden","year":"2021","journal-title":"JAMA"},{"key":"pone.0354237.ref011","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide","volume":"24","author":"JPH Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"pone.0354237.ref012","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued semaglutide vs placebo on weight loss maintenance","volume":"325","author":"D Rubino","year":"2021","journal-title":"JAMA"},{"issue":"24","key":"pone.0354237.ref013","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"AM Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0354237.ref014","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/obr.12772","article-title":"Determinants of weight loss maintenance: a systematic review","volume":"20","author":"RDM Varkevisser","year":"2019","journal-title":"Obes Rev"},{"key":"pone.0354237.ref015","article-title":"Long-term weight loss maintenance","volume":"82","author":"RR Wing","year":"2005","journal-title":"Am J Clin Nutr"},{"key":"pone.0354237.ref016","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g2646","article-title":"Long-term maintenance of weight loss with nonsurgical interventions","volume":"348","author":"SU Dombrowski","year":"2014","journal-title":"BMJ"},{"issue":"17","key":"pone.0354237.ref017","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","article-title":"Long-term persistence of hormonal adaptations to weight loss","volume":"365","author":"P Sumithran","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0354237.ref018","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/aje\/kwr224","article-title":"Validity of a multipass, web-based, 24-hour self-administered recall for assessment of total energy intake in blacks and whites","volume":"174","author":"L Arab","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"2","key":"pone.0354237.ref019","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/sj.ejcn.1601768","article-title":"Relation between food intake and visual analogue scale ratings of appetite and other sensations in healthy older and young subjects","volume":"58","author":"BA Parker","year":"2004","journal-title":"Eur J Clin Nutr"},{"key":"pone.0354237.ref020","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/s41366-018-0119-9","article-title":"Long-term sustainability of changes in appetite after weight loss","volume":"42","author":"S Nymo","year":"2018","journal-title":"Int J Obes (Lond)"},{"key":"pone.0354237.ref021","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1530\/EJE-15-1116","article-title":"Long-term increased meal responses of GLP-1 and PYY after weight loss","volume":"174","author":"EW Iepsen","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"pone.0354237.ref022","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002517","article-title":"Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK","volume":"10","author":"T Weiss","year":"2022","journal-title":"BMJ Open Diabetes Res Care"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:23:24Z","timestamp":1785173004000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354237"}},"subtitle":[],"editor":[{"given":"Alejandro","family":"Torrado Pacheco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0354237","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}